How does Evista (raloxifene) work?

Evista (raloxifene) is not a hormone, it mimics the action of estrogen on bones while at the same time blocking the effect of estrogen on other tissues. It is known as an estrogen agonist/antagonist (formerly called a selective estrogen receptor modulator [SERM]) and this action decreases bone loss in postmenopausal women.

Using Evista long-term does not carry the same risk of cancer in breast and womb tissue that has been associated with estrogen-based hormone therapies. However, Evista can increase the risk of deep vein thrombosis and stroke and may increase the incidence of hot flushes and leg cramps. Evista may also be used to treat osteoporosis in postmenopausal women with invasive breast cancer. But evidence suggests it may not be as effective as bisphosphonates or estrogen at preventing bone loss.